Daniel Groener

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Cushing Syndrome Is Associated with Worse Survival and Higher Morbidity in Neuroendocrine Neoplasms.

Cushing Syndrome Is Associated with Worse Survival and Higher Morbidity in Neuroendocrine Neoplasms.

Journal: The Journal of clinical endocrinology and metabolism
Published: May 14, 2026

Real-World Efficacy and Safety of Lenvatinib and Sorafenib in Thyroid Cancer: A Retrospective, Propensity-Score-Matched Study.

Real-World Efficacy and Safety of Lenvatinib and Sorafenib in Thyroid Cancer: A Retrospective, Propensity-Score-Matched Study.

Journal: Thyroid : official journal of the American Thyroid Association
Published: April 13, 2026

Recent Advances and Future Trends of[18F]-Labeled PET Agents for Renal Imaging.

Recent Advances and Future Trends of[18F]-Labeled PET Agents for Renal Imaging.

Journal: Seminars in nuclear medicine
Published: September 10, 2025

Tubular MAG3 Extraction Rate is a Predictor of Short-Term and Long-Term Outcome After Kidney Transplantation: A Prospective Observational Study.

Tubular MAG3 Extraction Rate is a Predictor of Short-Term and Long-Term Outcome After Kidney Transplantation: A Prospective Observational Study.

Journal: Clinical nuclear medicine
Published: August 23, 2025

177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.

177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: July 12, 2025

Reply to "177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?"

Reply to "177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?"

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 07, 2025

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients.

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients.

Journal: European journal of nuclear medicine and molecular imaging
Published: February 10, 2025

Cancer-control outcomes with [177Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients.

Cancer-control outcomes with [177Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients.

Journal: Theranostics
Published: December 17, 2024

Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma.

Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma.

Journal: Clinical nuclear medicine
Published: December 17, 2024

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy.

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy.

Journal: JCO precision oncology
Published: December 06, 2024

Norepinephrine Transporter-Targeted Cancer Theranostics-New Horizons.

Norepinephrine Transporter-Targeted Cancer Theranostics-New Horizons.

Journal: Clinical nuclear medicine
Published: November 21, 2024

Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.

Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.

Journal: European journal of nuclear medicine and molecular imaging
Published: October 17, 2024
Showing 1-12 of 52

Last Updated: 09/26/2026